[go: up one dir, main page]

WO2004092210A3 - Molecule - Google Patents

Molecule Download PDF

Info

Publication number
WO2004092210A3
WO2004092210A3 PCT/SG2004/000098 SG2004000098W WO2004092210A3 WO 2004092210 A3 WO2004092210 A3 WO 2004092210A3 SG 2004000098 W SG2004000098 W SG 2004000098W WO 2004092210 A3 WO2004092210 A3 WO 2004092210A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
immunomodulatory activity
fve
polypeptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SG2004/000098
Other languages
English (en)
Other versions
WO2004092210A2 (fr
Inventor
Kaw Yan Chua
See Voon Seow
Prasanna Ratnakar Kolatkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
National University of Singapore
Original Assignee
Agency for Science Technology and Research Singapore
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore, National University of Singapore filed Critical Agency for Science Technology and Research Singapore
Priority to GB0523067A priority Critical patent/GB2417246B/en
Priority to US10/553,674 priority patent/US7998701B2/en
Publication of WO2004092210A2 publication Critical patent/WO2004092210A2/fr
Publication of WO2004092210A3 publication Critical patent/WO2004092210A3/fr
Anticipated expiration legal-status Critical
Priority to US13/172,909 priority patent/US8349334B2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

L'invention concerne un polypeptide Fve constitué d'un fragment, d'un homologue, d'un variant ou d'un dérivé de la protéine Fve, présentant au moins une activité biologique de la protéine Fve. L'invention concerne également les utilisations d'un tel polypeptide, etc., et des acides nucléiques codant pour ceux-ci, dans le traitement et la prévention de l'allergie et du cancer.
PCT/SG2004/000098 2003-04-17 2004-04-16 Molecule Ceased WO2004092210A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB0523067A GB2417246B (en) 2003-04-17 2004-04-16 Molecules having immunomodulatory activity
US10/553,674 US7998701B2 (en) 2003-04-17 2004-04-16 Molecule
US13/172,909 US8349334B2 (en) 2003-04-17 2011-06-30 Molecule

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308988.5A GB0308988D0 (en) 2003-04-17 2003-04-17 Molecule
GB0308988.5 2003-04-17

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10553674 A-371-Of-International 2004-04-16
US13/172,909 Division US8349334B2 (en) 2003-04-17 2011-06-30 Molecule

Publications (2)

Publication Number Publication Date
WO2004092210A2 WO2004092210A2 (fr) 2004-10-28
WO2004092210A3 true WO2004092210A3 (fr) 2005-06-30

Family

ID=9957008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2004/000098 Ceased WO2004092210A2 (fr) 2003-04-17 2004-04-16 Molecule

Country Status (3)

Country Link
US (2) US7998701B2 (fr)
GB (2) GB0308988D0 (fr)
WO (1) WO2004092210A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
TWI351963B (en) * 2003-09-17 2011-11-11 Yeastern Biotech Co Ltd Fungal immunomodulatory protein (fip) prepared by
WO2006132607A1 (fr) * 2005-06-10 2006-12-14 National University Of Singapore Allergenes mutants
US20070071766A1 (en) * 2005-09-23 2007-03-29 Ko Jiunn L Compositions comprising fungal immunomodulatory protein and use thereof
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
EP2010645A4 (fr) * 2006-04-20 2009-05-06 Univ Singapore Lactobacillus recombiné et utilisation de celui-ci
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP2572734B1 (fr) 2006-10-31 2016-04-06 East Carolina University Protéines de fusion à base de cytokine pour le traitement des troubles immunitaires
WO2009032949A2 (fr) 2007-09-04 2009-03-12 The Regents Of The University Of California Anticorps d'antigène de cellule souche anti-prostate (psca) à haute affinité pour un ciblage et une détection de cancer
ES2378870T5 (es) 2008-08-15 2016-02-03 Circassia Limited Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
WO2010018384A1 (fr) 2008-08-15 2010-02-18 Circassia Limited Peptide de l’antigène des cellules t d’allergène destiné à stimuler la production d’il-10
US8563690B2 (en) * 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
HRP20150317T1 (hr) 2009-02-05 2015-04-24 Circassia Limited Peptidi trave za cjepivo
EP2398504B1 (fr) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Procédés et kits pour le diagnostic d'un cancer et la prédiction d'une valeur thérapeutique
CA2757287C (fr) 2009-03-31 2019-09-10 East Carolina University Cytokines et neuroantigenes utilises dans le traitement de maladies immunitaires
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
CA2865676C (fr) * 2012-04-17 2020-03-10 Stefan Klostermann Procede d'expression de polypeptides faisant appel a des acides nucleiques modifies
US20160026765A1 (en) * 2013-03-15 2016-01-28 Phd Preventative Health Care And Diagnostics, Inc. Immunotherapy system and method thereof
US20150195880A1 (en) * 2014-01-06 2015-07-09 Lunera Lighting, Inc. Lighting system with built-in intelligence
TWI608846B (zh) * 2014-03-13 2017-12-21 益生生技開發股份有限公司 用於改善化學治療所造成之不良副作用的組合療法
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
EP3331564B1 (fr) 2015-08-07 2025-01-08 Imaginab, Inc. Constructions de liaison d'antigène se liant à des molécules cibles
WO2018147960A1 (fr) 2017-02-08 2018-08-16 Imaginab, Inc. Séquences d'extension pour dianticorps
CN107118263B (zh) * 2017-04-08 2020-07-03 张喜田 重组灵芝免疫调节蛋白突变体及其应用
US11945851B2 (en) 2017-06-07 2024-04-02 The Wistar Institute Of Anatomy And Biology MAGE-A vaccines and methods of treatment using the same
CN110261506A (zh) * 2019-06-26 2019-09-20 广东省微生物研究所（广东省微生物分析检测中心） 灵芝挥发性成分的hs-spme/gc-ms特征图谱及其构建方法和应用
TWI859701B (zh) * 2022-01-12 2024-10-21 蘑法生物科技股份有限公司 用於減緩及/或治療冠狀病毒疾病之免疫調節蛋白

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032866A1 (fr) * 1997-01-23 1998-07-30 Marie Curie Cancer Care Proteines hybrides permettant le transport intracellulaire et intercellulaire et utilisations de ces proteines
WO1999006544A1 (fr) * 1997-07-29 1999-02-11 The Immune Response Corporation Compositions a base de cytokine membranaire et procedes de modulation d'une reponse immune faisant appel a ces compositions
US5917026A (en) * 1996-02-05 1999-06-29 Loewenadler; Bjoern Fusion proteins of immunopotentiating activity
WO2002022680A2 (fr) * 2000-09-15 2002-03-21 Klaus Pfizenmaier Activation localement specifique, par l'intermediaire d'anticorps, d'une zytokine pro-apoptose : amaize (antibody-mediated apoptosis inducing zytokine)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040071718A1 (en) * 2002-09-18 2004-04-15 Jaw-Ji Tsai Local nasal immunotherapy for allergen-induced airway inflammation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917026A (en) * 1996-02-05 1999-06-29 Loewenadler; Bjoern Fusion proteins of immunopotentiating activity
WO1998032866A1 (fr) * 1997-01-23 1998-07-30 Marie Curie Cancer Care Proteines hybrides permettant le transport intracellulaire et intercellulaire et utilisations de ces proteines
WO1999006544A1 (fr) * 1997-07-29 1999-02-11 The Immune Response Corporation Compositions a base de cytokine membranaire et procedes de modulation d'une reponse immune faisant appel a ces compositions
WO2002022680A2 (fr) * 2000-09-15 2002-03-21 Klaus Pfizenmaier Activation localement specifique, par l'intermediaire d'anticorps, d'une zytokine pro-apoptose : amaize (antibody-mediated apoptosis inducing zytokine)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HSU HAO-CHI ET AL: "Fip-vvo, a new fungal immunomodulatory protein isolated from Volvariella volvacea", BIOCHEMICAL JOURNAL, vol. 323, no. 2, 1997, pages 557 - 565, XP002300842, ISSN: 0264-6021 *
KO JIUNN-LIANG ET AL: "A new fungal immunomodulatory protein, FIP-fve isolated from the edible mushroom, Flammulina velutipes and its complete amino acid sequence", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 228, no. 2, 1995, pages 244 - 249, XP008036978, ISSN: 0014-2956 *
KO JIUNN-LIANG ET AL: "Molecular cloning and expression of a fungal immunomodulatory protein, FIP-fve, from Flammulina velutipes", JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, vol. 96, no. 7, 1997, pages 517 - 524, XP008036979, ISSN: 0929-6646 *
MURASUGI A ET AL: "MOLECULAR CLONING OF A COMPLEMENTARY DNA AND A GENE ENCODING AN IMMUNOMODULATORY PROTEIN LING ZHI-8 FROM A FUNGUS GANODERMA-LUCIDUM", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 4, 1991, pages 2486 - 2493, XP002300843, ISSN: 0021-9258 *
PAAVENTHAN P ET AL: "A 1.7A Structure of Fve, a Member of the New Fungal Immunomodulatory Protein Family", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 332, no. 2, 12 September 2003 (2003-09-12), pages 461 - 470, XP004450110, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
GB2417246B (en) 2007-09-26
GB0523067D0 (en) 2005-12-21
US7998701B2 (en) 2011-08-16
GB2417246A (en) 2006-02-22
GB0308988D0 (en) 2003-05-28
WO2004092210A2 (fr) 2004-10-28
US20060275312A1 (en) 2006-12-07
US8349334B2 (en) 2013-01-08
US20120003259A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
WO2004092210A3 (fr) Molecule
WO2004047863A3 (fr) Produits geniques exprimes de maniere differentielle dans des tumeurs et leur utilisation
WO2004078777A3 (fr) Proteines protegees contre la dipeptidylpeptidase
WO2005042566A3 (fr) Peptides pour traitement et prevention de l'endometriose
ZA200500882B (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
WO2007087053A3 (fr) Compositions à base de variantes de bmp-7, procédés et utilisations
WO2004089982A3 (fr) Variantes april et leurs procedes
WO2005023979A3 (fr) Molecules d'acide nucleique de s. mansoni isolees et utilisations associees
AU2002258630A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2002018536A3 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
AU2002256019A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2003012103A3 (fr) Acides nucleiques codant de nouvelles proteines a boite f, leurs utilisations en diagnostic et en therapie
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
WO2004076613A3 (fr) Sequences d'acides nucleiques humaines provenant de carcinomes de la vessie
WO2003012102A3 (fr) Acides nucleiques codant des proteines a domaine hect
WO2005031350A3 (fr) Proteines acyltransferases humaines et leurs procedes d'utilisation
WO2003060148A3 (fr) Molecules d'acide nucleique regulees par l'androgene et proteines codees
WO2003099209A3 (fr) Compositions et procedes pour la recherche systematique et l'identification d'agents anti-vhc
AU2002257075A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2002303137A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2003062448A3 (fr) Acides nucleiques et polypeptides sqv
AU2003217864A1 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
AU2002258618A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2003044160A3 (fr) Molecules de la famille de proteines associees aux card et utilisations correspondantes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006275312

Country of ref document: US

Ref document number: 10553674

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 0523067.7

Country of ref document: GB

Ref document number: 0523067

Country of ref document: GB

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 10553674

Country of ref document: US